NCT07562022RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 93 (estimated)
- First submitted
- 24 Apr 2026
- Start date
- 9 Jun 2026
- Primary completion date
- May 2028
- Lead sponsor
- Sinocelltech Ltd.
- Diseases
- Follicular lymphoma
- NCT number
- NCT07562022
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 93
- From 9 Jun 2026 to the primary completion date, May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have lenalidomide exposure within 12 months prior to randomization
Other
- Documented refractoriness to lenalidomide.
Who the study is looking for
- Age 18-80 years old
- Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria
- Relapsed or refractory (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy
- Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion
- A measurable or evaluable disease at the time of enrolment
- ECOG PS 0-2
- Adequate organ function and bone marrow function
- Expected survival ≥ 6 months
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.